In a recent issue of Clinical Chemistry, De Wolf et al. described an evaluation of the new Procalcitonin (PCT) assay from Roche, performed according to CLSI (Clinical and Laboratory Standards Institute) recommendations, compared with the widely accepted PCT assay on the Brahms Kryptor analyzer (Brahms) (1 ) . We recently carried out an analogous study on a Cobas e411 (Roche Diagnostics) (2 ) and reached some different conclusions. We found no transferable results between the Elecsys Brahms PCT (Cobas) and PCT-TRACE (Kryptor) when we compared 152 samples from the same number of different patients. A regression analysis demonstrated the heteroscedasticity of the results as well as the lack of normality of the residuals. PassingBablock nonparametric analysis showed a proportional tendency toward lower PCT concentrations on the Cobas than the Kryptor analyzer. The regression equation was: PCT Cobas ϭ Ϫ0.0024 ϩ 0.8586 PCT Kryptor (intercept 95% CI, Ϫ0.0061 to 0.0051; slope 95% CI, 0.84 -0.87). We created a folder empirical cumulative distribution plot (mountain plot) to compare both methods, following the CLSI-EP21A recommendation for situations in which differences do not follow a gaussian distribution. The mountain plot was not fully included among the specification lines, the graph was biased toward positive differences between methods, and an outlier was detected (2 ) . Less than 95% of the differences were included within the tolerance limits (defined by the 2.5th and 97.5th percentiles, respectively), and on the basis of these results we concluded that there was not transferability between both methods. Because the same analytical handling conditions were followed in both studies, this point could not explain the discrepant results. A similar range of concentrations were compared in both studies, but a different percentage of low concentration samples were assayed (70% of the PCT values were Յ0.25 ug/L in the study by de Wolf et al. compared to 28% in our study), probably due to the fact that de Wolf et al. included only patients with lower respiratory tract infections, whereas we also included patients with sepsis who were hospitalized in the intensive care unit. In our study the tendency toward lower values on the Cobas analyzer was confirmed over the entire measuring range. With regard to concordance between the 2 assays, de Wolf et al. found 99% and 98% at cutoff values of 0.25 ug/L and 0.5 ug/L, respectively, whereas we found a slightly lower grade of concordance of 97% and 94% for the same cutoff values.
It is beyond the scope of this communication to state whether a reappraisal of the cutoff is necessary, because this was not a clinically based study. However, if the present lack of transferability is confirmed in the clinical management of the patients, it would be interesting to open up further discussion about the best cutoff points of the new Elecsys Brahms PCT method, not on the basis of calculated predictions but rather clinical findings. 
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